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NOTES

THE BIOTECHNOLOGY PROCESS PATENT ACT
OF 1995: PROVIDING UNRESOLVED AND
UNRECOGNIZED DILEMMAS IN U.S. PATENT
LAW
I. INTRODUCTION
While the term "biotechnology" was coined early in the twentieth century,' the
use of biotechnology processes dates back almost as far as the beginning of
humankind. 2 Over 10,000 years ago, our early ancestors utilized biotechnology
as they began raising crops and domesticating animals,3 and by 2000 B.C. the
ancient Sumerians were using yeast in fermentation processes for brewing, baking,
and cheese production.4 Centuries later, in 1797, biotechnology penetrated the
world of medicine and healthcare when Edward Jenner produced a small pox
5
vaccine from cowpox.
Not until the nineteenth century, however, did scientists begin to understand
the chemical and biological bases for these developments.6 Specifically, the
nineteenth century marked several important scientific breakthroughs, including
Louis Pasteur's discovery of yeast in the fermentation process, Gregor Mendel
and Charles Darwin's work on heredity, and Schleiden and Schwann's discovery
of the cell, all of which helped open the door for modem biotechnology.7 Today
biotechnology is a booming industry, generating billions of dollars and producing
innovations ranging from new antibiotics to cloned animals and geneticallymodified food products.'

' Francis C.R. Manning, Biotechnology: A Sdenfific Perspeclive, in THE INTERNAI1ONAL POLICS
oiF B1OTIECHNO .OGY: INVIi'GA'IIN(; GI.OBAI.FuTURI.-S 13, 13 (Alan Russell &John Vogler eds.,

2000).
2 LSA YOUNT, BiOTECHNOI.OGY AND GENETIC ENGINEERING

3 (2000).

SId at 3.
'
5

Manning, supra note 1, at 15.
Id at 15.

6 YOUNT,

supra note 2, at 3.

Id at 3-4.
46-59 (2003);
6-10 (1996).
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The commercialization of biotechnology has led researchers and corporations
to seek patent protection for their biotechnological innovations. As the courts
and the Patent and Trademark Office increasingly have allowed patents for these
inventions, the biotechnology industry has demanded enhanced patent protection.
In 1995, this demand led Congress to pass the Biotechnology Process Patent Act,'
a specialized piece of legislation providing an exemption from the
nonobviousness requirement for biotechnology processes.
This Note first addresses the historical and scientific background of the
Biotechnology Process Patent Act of 1995. Next, this Note considers the Act's
practical effects on our nation's patent law, including problems that the Act
currently creates. Finally, this Note proposes a possible solution to these
problems in the form of corrective legislation.
II. BACKGROUND
A. THE LAW

The United States Constitution grants Congress the power "to promote the
Progress of Science and useful Arts, by securing for limited Times to Authors and
Inventors the exclusive Right to their respective Writings and Discoveries."'" The
First Congress was quick to exercise this power, passing the Patent Act of 1790
in the early days of its first session. 1 Since that time, subsequent Congresses have
contributed to the growth and development of the United States patent system
through such means as the formation of the Patent and Trademark2Office (PTO)
and the creation of the Court of Appeals for the Federal Circuit.'
Today the PTO reviews patent applications to ensure that they meet the
following five legal requirements: (1) patentable subject matter, (2) utility, (3)
novelty, (4) nonobviousness, and (5) enablement. 3 While all five requirements
are necessary for patentability, many judges and scholars regard nonobviousness
as the key requirement, in part, because it is frequently the most challenging to
prove." Courts have considered nonobviousness in determining patentability
since at least 1851;15 however, Congress did not codify the nonobviousness

Pub. L. No. 104-41 (codified at 35 U.S.C.
U.S. CONS'f. art. I, § 8, ci. 8.
Act of Apr. 10, 1790, ch. 7, 1 Stat. 109.

+RoBIlTlP.MI\4i

(;B

§

103, 282 (2003)).

Br AI..,I1BfJ J.B( IUAj.lPR'iY IN THB NEWT('.E;HNOI.( );A.AAE,

110 (Erwin Chemerinsky et al. eds., Aspen Publishers, Inc., 3d ed. 2003).
13 Id.at 112.

" Id.at 112.

15 See Hotchkiss v. Greenwood, 52 U.S. (11 How.) 248 (1851).
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requirement until The Patent Act of 1952.6 Since the 1952 Act, the statutory
requirement for nonobviousness has required that an inventor may not obtain a
patent on an invention where "the subject matter sought to be patented and the
prior art are such that the subject matter as a whole would have been obvious at
the time the invention was made to a person having ordinary skill in the art to
which said subject matter pertains."' 7
The Graham Court and courts since have repeatedly emphasized that
nonobviousness is a question of law which requires highly factual inquiries on a
case-by-case basis." To determine the obviousness of a particular invention, a
court must make three main factual inquiries, evaluating (1) "the scope and
content of the prior art," (2) "differences between the prior art and the claims at
issue," and (3) "the level of ordinary skill in the pertinent art."' 9 Other
"secondary considerations," including "commercial success, long felt but
20
unsolved needs, [and the] failure of others," may also be relevant.
The range of patentable subject matter under the patent code is quite
expansive, including "any... process, machine, manufacture,... composition of
matter, or... improvement thereof."' 2' The courts have interpreted this broad
language to have a wide scope, declaring in 1980 that live, human-made
microorganisms may qualify as compositions of matter and thus may be
patentable.
That Supreme Court decision in Diamond v. Chakrabary was a
significant advance for biotechnology product patents. Since at least 1974,
however, lower courts had already been finding biotechnology processes
23
patentable.
1. Nonobviousness and Biotechnology ProcessPatents: The Beginnings. In 1974, the
Court of Customs and Patent Appeals held that use of a novel starting material
may establish the nonobviousness of a biotechnology process, even when the
steps of that process are part of the prior art.24 In In reMang,the patent applicant
applied a known method of aerobic cultivation to a new strain of Streptomyces

M 35 U.S.C. §5 1-376 (1952) (current version at 35 U.S.C. § 1-376 (2003)); Graham v. John
Deere Co., 383 U.S. 1 (1966).
7 35 U.S.C. § 103(a) (2003).
Graham, 383 U.S. at 17.
19 Id.

2(Id.

2'35 U.S.C. § 101 (2003).

22 Diamond v. Chakrabarty, 447 U.S. 303, 206 U.S.P.Q. (BNA) 193 (1980).
21 See, e.g., Inre Mancy, 499 F.2d 1289,182 U.S.P.Q. (BNA) 303 (C.C.P.A. 1974) (allowing patent

protection for a biotechnological process). The first biotechnology process patent may actually have
been awarded to Louis Pasteur in1893 for a microbial fermentation process. Manning, supra note
1, at 15.
21 In re Many, 499 F.2d 1289.

Published by Digital Commons @ University of Georgia School of Law, 2004

3

Journal of Intellectual Property Law, Vol. 12, Iss. 1 [2004], Art. 8

J. INTELL PROP.L

[Vol. 12:229

to produce the antibiotic daunorubicin. 25 The court reasoned that the statutory
standard for nonobviousness necessitates a consideration of the process
"invention as a whole," which includes the application of the known cultivation
26
method to the previously unknown Streptomyces bifurcus microorganism. The
court explicitly rejected the Patent Board's argument that one skilled in the art
produce daunorubicin,
would find it obvious to cultivate the novel strain to
27
stating that "one cannot choose from the unknown."
The Many court also distinguished between a method of using a novel product,
as involved here, and a method of making a novel product, as involved in previous
28
cases in which the court rejected process patents on nonobviousness grounds.
The court emphasized that section 103 of the Patent Code requires an evaluation
of the process "invention as a whole," which includes the starting materials as well
as the methods applied to them. 29 Based on this premise, the court suggested that
the use of a novel starting material establishes the nonobviousness of the process
as a whole while a novel resultant product does not speak to the obviousness or
nonobviousness of the process.3"
2. ChemicalProcess Patents and In re Durden: The Trouble Begins. In 1985, the
Court of Appeals for the Federal Circuit decided In rV Durden, holding that a
chemical process, otherwise obvious, is not patentable simply because either or
both the specific starting material and the product obtained are novel and
nonobvious.3 1 In Durden, Judge Rich, who had written the Mangy opinion just
eleven years earlier,32 stated that the novelty of the starting material as well as the
novelty of the resultant product makes the process novel but not necessarily
nonobvious.3 In the course of the opinion, Judge Rich distinguished Durden from
several previous chemical process cases but failed to mention the Mangy decision
even once.3 4 This suggests that he may have considered Manfg inapplicable
because it concerned a biotechnology process.
Judge Rich also stressed that the court was not setting forth a per se rule of
obviousness, declaring that courts must decide each obviousness case "on the
25 Id.
26 Id. at
27 Id at

1292.
1293.

28 Id
29 Id. at

1292.

30 See id at 1293 (noting that the novelty of the starting material may lend nonobviousness to

a method of use while the novelty of the product may not lend such nonobviousness to a process

of making).
31 In re Durden, 763 F.2d 1406, 226 U.S.P.Q. (BNA) 359 (Fed. Cir. 1985).
32 Donald G. Daus, New U.S. Legislation: Biotechnology Process Patents-A Legislative Change and
Administrative Expansion, 12 INTELL. PROP. J. 333, 338 (1997).
33 In re Durden, 763 F.2d at 1410.
34 Id
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basis of its own particular fact situation. ' '5 Somewhat prophetically, Judge Rich
warned against extracting a general rule from Durden, noting that "today's rule
would likely be regretted in tomorrow's case."36 Despite this warning, over the
next ten years, the PTO repeatedly relied on Durden to deny process claims,
including biotechnology and software patents outside the realm of traditional
chemical patents.37

3. The Court's Attempt at a Remedy: Drawing a Distinction Between Using and
Making. In 1990, five years after Durden, the Court of Appeals for the Federal
Circuit was again confronted with a chemical process patent rejected on
nonobviousness grounds. 38 This time around Judge Rich, again writing for the
court, held that the chemical process was not obvious and the applicant was
therefore entitled to his method claims. 39 Rather than overturning Durden,
however, Judge Rich attempted to distinguish the case. Specifically, he drew a line
between methods of making novel compounds, as involved in Durden, and
methods of using those compounds, as involved in Pleuddemann.4 ° Judge Rich
seemed to suggest that the latter are nonobvious on the basis of the novelty of the
compounds while the former are not.4' At the same time, however, Judge Rich
acknowledged that Durden actually involved both a method of making a novel and
nonobvious product and a method of using a novel and unobvious starting
material, admitting that "there 2 were unobvious starting materials used and
4
unobvious products obtained.

Not surprisingly, the Pleuddemann court's artificial distinction between using
and making only added to the confusion within the PTO and the larger legal
community." While patent attorneys could reasonably try to phrase process
claims as "processes of using" rather than "processes of making," many
commentators lamented the difficulty of predicting when patent examiners would
accept those claims and when they would instead reject the claim as a Durden-type

Id.
SId. at 1411.
31 E.g., Exparte C, No. 92-0393, 1992 WL 515817, 27 U.S.P.Q.2d (BNA) 1492 (Bd. Pat. App.
& lnterf. Sept. 28, 1992) (citing In reDurden to deny a biotechnology process claim on obviousness
grounds).
" In arPleuddemann, 910 F.2d 823, 15 U.S.P.Q.2d (BNA) 1738 (Fed. Cir. 1990).
39 Id.
, Id.at 826.
' See id at 828 (stating that the obviousness of the appellant's method claims "depends on the
obviousness of using appellant's new compounds").
'2Id.at 827.
43 See Dan L. Burk, Biotechnology and Patent Law: Fiting Innovation to the Procrustean Bed,
17
RUT iRS C)MPUTlFt & TiNCH.L.J. 1, 57 (1991) ("Without a cogent explanation of the standard to
apply, there is no reason to believe that the PTO is now more capable of distinguishing a Mancy
situation from a Durden situation than it did in the past.").
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"process of making" claim in disguise.44 Some legal commentators further
worried that this increased uncertainty in the patent law would have a detrimental
effect on the biotechnology industry. This concern spread to biotechnology
4
companies who then lobbied Congress for greater patent protection. "
4. Congress Tries to Step In: FailedLegislative Remediesfrom 1990 to 1995. In the
101 st Congress, Representative Boucher and Senator DeConcini introduced the
Biotechnology Patent Protection Act of 1990 to the House and Senate,
respectively.46 These companion bills were intended to resolve the "Durden
dilemma" by providing a nonobviousness exemption for process patents in
general.47 Specifically, the legislation would have added a new paragraph to
section 103 of Title 35, stating that "a process of making a product shall not be
considered obvious under this section if an essential material used in the process
'4
is novel under Section 102 and otherwise nonobvious under Section 103."
After introducing these bills, the congressmen solicited the opinion of the
Department of Commerce, which agreed on the need for legislation but objected
to the proposed bill on several grounds, including the extension of enforcement
rights "of a patent claiming biotechnological material used in the manufacture of
a recombinant product., 49 In response to these concerns, Representative
Boucher introduced a second bill, House Bill 5664, which provided a
nonobviousness exemption to process patents, ° but the 101st Congress took no
further action on this legislation."'
In the 102d Congress, Representative Boucher and Senator DeConcini
introduced the Biotechnology Patent Protection Act of 1991, again through
companion bills in the House and Senate,52 with identical language to House Bill
5664 from the previous Congress. 3 The Senate passed the bill with an
amendment that limited the scope of the legislation from processes in general to
biotechnology processes only. s4 In the House, Representatives considered the bill
in the Committee on the judiciary, where opponents of the bill suggested that the

" See, e.g., David Beier & Robert H. Benson, Biotechnologe PatentProtectionAct, 68 DENV. U. L.
ReV. 173, 178-80 (1991) (explaining the difficulty in predicting how the Patent Office and Federal
Circuit would treat process claims after Pleuddemann).
4' Timothy P. Linkkila & Timothy E. Tracy, Biotechnology Process Patents: Is Special Legislation
Needed?, 5 RISK 177 (1994).
' HR. 3957, 101st Cong. (1990); S. 2326, 101st Cong. (1990).
47 136 CONG. REc. 5,182 (1990); 136 CONG. REC. 1482 (1990).
48 136 CONG. REc. 5,182 (1990).
49 S. REP. NO. 102-260, at 2 (1992).
50 H.R. 5664, 101st Cong. (1991).
s,S.REP. No.102-260, at 2 (1992).
52 H.R. 1417, 102d Cong. (1991); S. 654, 102d Cong. (1991).
11 S. REP. No.102-260, at 3 (1992).
14 H.R. REP. No. 102-1085, at 109 (1992).
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legislation was "unnecessary" and, rather than alleviating the current uncertainty
in the law, would actually "create new uncertainty."55 Opponents also worried
that the bill was "overly broad" and would apply to inventions outside the field
of biotechnology, including inventions "inthe areas of electronics, computer
technology, chemicals, mechanical engineering and machinery."56 The Committee
reported that it did not have time in the remaining days of the 102d Congress to
adequately consider amended Senate Bill 654, which may have addressed the
Committee's concerns, and the issue was therefore left for the next Congress.57
In the first session of the 103d Congress, the Senate passed the Biotechnology
Patent Protection Act of 1993, which, like the amended Senate Bill 654, was
limited exclusively to biotechnology processes." The House, however, in the
second session of the same Congress, considered a separate bill, House Bill 4307,
which was not restricted to biotechnology processes but was "a middle ground
approach which is neither industry-specific [n]or totally generic."' 9 Opponents
of this generalized approach again defeated the legislation, and the 103d Congress
ended without the passage of either version of the bill."°
5. TheBiotechnologyProcessPatentActof1995. On November 1, 1995, the 104th
Congress passed the Biotechnology Process Patent Act of 1995,6" and President
William J. Clinton promptly signed the bill into law.62 Most notably, the Act
amended Title 35 of the Patent Code, designating the former section 103
language, which sets forth the nonobviousness requirement for patents, as
subsection (a) and adding a new subsection (b) which provides an exemption
from the nonobviousness requirement for biotechnology processes using or
resulting in novel and nonobvious compositions of matter.63
In order for this exemption to apply, the patent applicant must both expressly
assert the exemption and claim the process and composition of matter in the
same application or in separate applications having the same effective filing date.64
Additionally, the process patent must include claims to the composition of matter
and be set to expire on the same date as the composition of matter patent.65

s'Id at 109.
56

Id at 109.

57 Id
51

139 CONG. R-(:. S8815-06, 15792 (1993).
140 CONG. Ri C. 24911 (1994).

¢ 141 CONG. REC(. 21543 (1995).
61 Pub. L. No. 104-41 (codified at 35 U.S.C.
62 1995 U.S.C.C.A.N. 404-1 (1995).
63 35 U.S.C. § 103.
64

103, 282 (2003)).

Id

65 Id.
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Finally, the claimed process must fall within the statutory definition of
"biotechnology process," as provided in section 103(b).66
The legislative history indicates that Congress's main purposes in enacting this
legislation were to "resolve the delays and inconsistent determinations faced by
biotechnological process patent applicants under present PTO practices" and to
close a loophole in the Process Patent Amendments Act of 1988, thereby
providing American inventors with greater protection from competitors abroad.67
In regards to the first purpose, the HouseJudiciary Committee noted that the bill
and its predecessors were developed in response to "two conflicting and
irreconcilable decisions" by the Court of Appeals for the Federal Circuit: Durden
and Pleuddemann.68 The Committee lamented the PTO's reliance on Durden in
rejecting biotechnology process claims on nonobviousness grounds as well as the
confusion caused by the using-making distinction described in Pleuddemann.F
Both the House and the Senate anticipated that the Biotechnology Process Patent
Act of 1995 would relieve confusion within the PTO and provide certainty for
patent applicants.7"
The legislative history also reveals, to some extent, Congress's intent in
limiting the nonobviousness exemption to biotechnology processes rather than
setting forth a broad exemption that would apply to process patents in general.71
Specifically, members of both the House and the Senate recognized the failure of
previous legislation that would have established a broad nonobviousness
exemption for process patents.72 Presumably, the drafters of the Biotechnology
Process Patent Act limited its scope to biotechnology processes in order to pass
the legislation, a goal they finally achieved at last in 1995, a full ten years after the
Durden decision and five years after Pleuddemann.73

66

Id.

1,H.R. REI'. Nt). 104-178, at 1-2 (1995), reprinted in 1995 U.S.C.C.A.N. 395, 395-396; see also 141
CON;. Ri (,. 28072 (1995) (statement of Sen. Hatch) (stating that the purpose of the legislation is
to "resolve delays and inconsistent determinations faced by biotechnology patentees under present
PTO practices").
61 H.R.RI'. No. 104-178, at 3.
69 Id.
I" H.R. RiP.No. 104-178, at 5; 141 CONG. Rzc:. 21543 (1995) (statement of Sen. Hatch).
H.R. RE'. No.104-178, at 4-5; 141 CON;. Ri--:. 21543 (1995) (statement of Sen. Hatch).
See H.R. Ri-i'. No. 104-178, at 4-5 ("Although industry specific legislation, particularly in the
context of patent law, is generally not favored,. . . predecessor bills, such as HR. 4307, made their
enactment unlikely."); 141 CoNG. Rix:. 21543 (1995) (statement of Sen. Hatch) ("The House version
of the bill introduced last year was drafted to address issues broader than biotechnology industry,
due to then Chairman Hughes' insistence that the measure not be industry specific, an approach
which was not acceptable to the Senate.").
" Biotechnology Process Patent Act of 1995, Pub. L. No. 104-41 (codified at 35 U.S.C. %] 103,
282). Though limiting the scope of the legislation may have compromised Congress's goal of
7'

72
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6. The FederalCircuit'sFollow-up: In re Ochiai, In re Brouwer, and Torpharm,
Inc. v. Ranbaxy Pharmaceuticals, Inc. Just one month after President Clinton
signed the Biotechnology Process Patent Act of 1995 into law, the Federal Circuit
decided In re Ochiai, holding that a chemical process was not obvious when the
process utilized a novel and nonobvious starting material to create a novel and
nonobvious product.74 Although the facts of the case reveal that both the starting
material and the resulting product were novel and nonobvious, the court
emphasized the relevance of the starting material in its nonobviousness
determination. Specifically, the court cited Mangy with approval, concurring with
the Mangy court's reasoning that "one cannot choose from the unknown," to
support the conclusion that a novel, nonobvious starting material establishes the
nonobviousness of the process. 5
In its analysis, the court failed to recognize a distinction between the law on
biotechnology processes and that on chemical processes. In particular, the court
noted that Mangy involved "a highly analogous set of facts" 76 without
distinguishing between the biotechnology and chemical subject matter of the two
cases. Additionally, the court neglected to point out that the recently enacted
Biotechnology Process Patent Act of 1995 would apply to the facts of the Mang
case but not to the facts of Ochiai.
Despite the fact that the Ochiaicourt arrived at the opposite result of Durden
under facts "identical to those that occurred in the Durden decision,"77 the Ochiai
court avoided explicitly overruling Durden by directly contradicting itself and
suggesting that the facts of Durden are actually in some way distinguishable from
those of Ocbiai.7 8 Specifically, the court asserted that the patent examiner
'
incorrectly applied the Durden case which is one "turning on specific facts,"79

eliminating inconsistent determinations in the Patent Office, the successful passage of this legislation

did allow Congress to meet its second goal of closing a loophole in foreign trade policy. As one
commentator noted, this loophole posed a unique problem for biotechnology companies; that is,
"while claims to transformed host cells may be patentable and readily granted, they have only limited

commercial value insofar as a third party is able to freely import the protein made offshore, free
from the scope of the Omnibus Trade and Competitiveness Act of 1988 and free from exclusion
via the International Trade Commission." Harold C. Wegner, Biotechnologv Process Patents: Judialor
Legislative Remedy, 73J. PAi. &TRAlIEMARK Oii. So(:'Y 24,25(1991). By passing the Biotechnology
Process Patent Act of 1995, Congress could close this loophole, thus satisfying the monetary
motivation which drove biotechnology companies to seek legislation in the first place.
14 In re Ochiai, 71 F.3d 1565 (Fed. Cir.
1995).
'5 Id at 1570.

Id.
SId -at1568.
7 See id at 1570.
76

79

Id.
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thereby implying some significant peculiarity in the facts of Ochiai which makes
the Durden decision inapplicable.
Three months later, the Federal Circuit decided In re Brouwer, holding that a
chemical process is not obvious where the resulting product is new and
nonobvious. s Like the Ochiaicourt, the Brouwercourtnoted that nonobviousness
is a highly fact-specific inquiry,8 Unlike the Ochiai court, however, the Brouwer
court could not rely on the Many court's argument that "one cannot choose from
the unknown" to back up its holding because, under the facts of Brouwer,only the
resulting product, and not the starting material, was novel and nonobvious. 2
Again, the court avoided explicitly overruling Durden, instead rejecting it as
inapplicable.83
More recently, inJuly 2003, the Federal Circuit held in Topharm, Inc. v. Ranbaxy
Pharmaceuticals,Inc. that the owner of a chemical process patent was not estopped
from arguing that the patent was nonobvious.84 The court came to this
conclusion even though the patent owner had originally defended against the
patent examiner's nonobviousness objection by relying on the novelty of the
product, which was later discovered not to be novel.85 The court gave three
reasons for its holding: (1) the plaintiff in this case actually had made two
separate arguments for the nonobviousness of the process, and the other
argument may still have been valid, (2) the appellee's argument of the form "If p,
then q. Not p. Therefore, not q." is a logical fallacy, and (3) a patent examiner's
reasons may be challenged so that, even if he only found the process nonobvious
based on the novelty of the product, a process patent may still be valid on other
grounds if the novelty of the product fails."6 While the patent examiner's finding
of nonobviousness on the basis of the novel resultant product was not in
question, as the product was not truly novel, the Torpharm court suggested that,
contrary to Brouwer,novelty of the product may not always be adequate to support
a finding of nonobviousness of the process. "7 Specifically, the court asserted that
"a process yielding a novel and nonobvious product may nonetheless be obvious;
8
conversely, a process yielding a well-known product may yet be nonobvious.""
In other words, the Torpharm court suggested, as the Many court did twenty-nine
years earlier, that a new and nonobvious product is not determinative, and may

In reBrouwer, 77 F.3d 422 (Fed. Cir. 1996).
s'Id. at 425.
S'
See id at 424 (noting that the claimed process results in a new, nonobvious product).
3Id.
at 425-26.
336 F.3d 1322, 67 U.S.P.Q.2d (BNA) 1511 (Fed. Cir. 2003).
,' Id
' Id.
at
"' Id.at

1329.
1327.

Id
https://digitalcommons.law.uga.edu/jipl/vol12/iss1/8
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not even be relevant, 8to an assessment of the obviousness of a chemical or
biotechnology process. 1
B. THE SCIENCE

Biotechnology in the scientific world is broadly defined as "the manipulation
of organisms or their components to perform practical tasks or provide useful
products."9 ° The science of biotechnology includes a vast array of practices from
fermentation to antibiotic production to sewage treatment to genetic engineering
and gene therapy.9 "Biotechnology" as defined by section 103(b) of the Patent
Code, however, is somewhat different" Specifically, section 103(b) defines a
"biotechnology process" as follows:
(A) A process of genetically altering or otherwise inducing a singleor multi-celled organism to(i) express an exogenous nucleotide sequence,
(ii) inhibit, eliminate, augment, or alter expression of an
endogenous nucleotide sequence, or
(iii) express a specific physiological characteristic not naturally
associated with said organism;
(B) cell fusion procedures yielding a cell line that expresses a
specific protein, such as a monoclonal antibody; and
(C) a method of using a product produced by a process defined by
(A) or (B), or a combination of subparagraphs (A)
subparagraph
93
(B).
and
In other words, the statutory definition of a biotechnology process purports
to include only two general types of procedures, genetic alteration and production
of cell lines, which the statute further restricts in scope.
1. Genetic Alteraion. Genetic alteration, in general, is the manipulation of
genetic material, or deoxyribonucleic acid (DNA).9 All living cells possess DNA,

Id; In re Manqy, 499 F.2d at 1293.
Bioj,o(;y 364 (5th ed. 1999). See also BoRFEM FT AJ,., supra note
)Niji, A. C,\MtIBII, 1 ,l,.,
8, at 2 (defining biotechnology as "any technology associated with the manipulation of biological
systems").
" OxpooD Di(-znoNARtYou)B CHEFMTIsRY AND MOJ.FCUJAR Boj.o;Y 72 (A.D. Smith et al.
eds., 2000).
" ee 35 U.S.C. § 103(b) (defining a biotechnology process).
89

" Colin R Harwood & Anil Wipat, Genome Management and Ana~sis: Prmkayotes, in BASIC
BioT'IV.CHNOjLo(;y 65 (Cohn Ratledge & Bjomn Kristiansen eds., 2d ed. 2001).
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which are complex molecules which code for the production of proteins." These
proteins, in turn, drive all of the basic functions of life.9 6 Specifically, each DNA
molecule is composed of two polynucleotides associated to form a double helix.97
On the inside of this helix is a series of nucleic acid base pairs.98 There are only
four nucleic acid bases which always pair the same way: adenine with thymine and
guanine with cytosine.' 9 The sequence of these base pairs carries the organism's
genetic information, providing instructions for the production of proteins (via
ribonucleic acid (RNA))."t In particular, series of three bases, called codons,
encode for twenty specific amino acids which join together in certain
combinations to compose specific proteins.'' These proteins play a central role
in regulating the cell's functions and in determining the physiological
characteristics of the organism as a whole. 2
The statute describes genetic alteration as those procedures which stimulate
a living thing to (1) express an exogenous nucleotide sequence, (2) change the
expression of an endogenous nucleotide sequence, or (3) express a physiological
trait not naturally associated with the organism.' °3 "Expression" of a nucleotide
sequence refers to the process of protein synthesis from the genetic code.' °4
Expression of an exogenous nucleotide sequence thus involves an organism
responding, via protein synthesis, to genetic information originating outside the
organism. This new genetic information may be incorporated into an organism's
pre-existing DNA through a number of recombinant DNA techniques.0 5 For
example, in gene splicing, scientists use proteins called restriction enzymes to cut
DNA molecules at specific locations and then insert foreign DNA, from the same
or different species, at these locations. 6 Similarly, altering the expression of an
endogenous nucleotide sequence refers to a process of inducing an organism to
express its original genetic material differently by starting, ceasing, or otherwise
adjusting the production of certain proteins.

BoRiiM E Al.., supra note 8, at 3.
'x Id
15

97 H. RoBE.RT HORTON FT Al.., PRINCIPL-.S OF BIoCHF.MISTRY 12 (3d ed. 2002).

" MICHAFJ. T. MADI(;AN .T AI.., BiOI.O(;Y OP MICROORGANISMS 171 (10th ed. 2003).
99 Id

HORiON
A., spra
s
note 97, at 12; MADIGAN
n0 MADIGAN ET Al.., supra note 98, at 194.
'N

T A,

supra note 98, at 171.

11,2See CAMPBEILL F' Al., supra note 90, at 68 (describing the many functions of proteins).

35 U.S.C. § 103(b).

David B. Archer et al., Genetic Engineenng

Yeasts and Filamentous Fungi, in BASI

Bli('nHNOILO;Y 96 (Colin Ratledge & Bjom Kristiansen eds., 2001).
'5 See YOUNT, supra note 2, at 6-8 (describing the development of recombinant DNA

procedures); Harwood & Wipat, supranote 94, at 66-81 (detailing genetic engineering techniques).
"' YOUNT, supra note 2, at 7.
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The third type of genetic alteration within the statutory definition involves the
expression of a new physiological characteristic." 7 This category is significantly
more expansive than the previous two, apparently covering processes which do
not involve the manipulation of DNA and thus are not processes of genetic
alteration in the scientific sense. Specifically, a new physiological characteristic
broadly refers to any change in the normal functioning of a living organism.' 8
The exact scope of this clause is somewhat vague and depends upon the
definition of the word "express," which in the context of the statute may be
interpreted either as a genetics term of art or in its generic sense.
As mentioned earlier, expression in the field of genetics refers to the process
of synthesizing proteins from the genetic code."°9 Applying this definition would
limit the scope of clause (iii) to those physiological changes which result from
altered protein synthesis due to adjustments in the genetic code. This
interpretation, however, would render clause (iii) superfluous given that the
previous two clauses already cover such genetic alterations. That is, at a basic
level, clause (i) covers processes incorporating outside genetic information while
clause (ii) covers all other genetic alterations, specifically those involving changes
to the organism's original DNA. Additionally, the statute refers to "a process of
genetically altering orothermise induine' new physiological characteristics. 10 Since,
"otherwise inducing" cannot apply to either of the previous clauses (because
changes in nucleotide sequences are, by definition, processes of genetic
alteration"'), these words too would be rendered superfluous if not applied to
clause (iii).
The difficulties surrounding the term of art definition suggest that "express"
2
should be interpreted in its generic sense to denote an outward manifestation."
Under this extremely broad-but perhaps necessary-interpretation, any
procedure which stimulates an organism to manifest an unnatural physiological
characteristic (i.e., to change its normal functioning) is a biotechnology process
under the statute. This definition could include procedures, such as injecting an
organism with an inorganic chemical compound, which are beyond the bounds
of genetic alteration in the scientific world.

35 U.S.C. § 103(b).
WIEBS.I.FR'S II: NW Riviut-sInI") , UNIVEI.A,'Y DICnoNARY 887 (Anne H. Soukhanov et al.
WE
eds., 1984).
"'J Archer et al., spra note 104, at 96.
35 U.S.C. 5 103(b) (emphasis added).
. See CAMPBI. J, F.T AI ., supra note 90, at 6-7 (noting that genetic information is encoded in the
nucleotide sequences of DNA).
12 Se' WF.BSTIR'S II: NiEw Rivi.RsII)i. UNIVIV.ISI'IY DItiONARY, supra note 108, at.455
(defining "express" and "expression").
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2. The Productionof CellLines. The second statutory category of biotechnology
process involves the production of cell lines. Cell lines are populations of cells
cultured in vitro (i.e., outside a living organism) that are descended from a single
primary culture." 3 These cells have common characteristics,' 14 and for this
reason, researchers frequently utilize cell lines to produce specific proteins."' The
statute expressly mentions monoclonal antibodies, which are immune proteins
secreted by a clone of cells, 6 as an example of such a protein. Because these
proteins specifically bind to particular antigens (i.e., foreign agents, such as
bacterial and viral molecules, which elicit an immune response)," 7 monoclonal
antibodies are particularly useful in laboratory research, clinical diagnosis, and the
treatment of disease." 8 The statute limits the production of cell lines, however,
to those which result from cell fusion procedures, leaving out other production
methods. 19
Additionally, the statute fails to incorporate numerous procedures involving
isolated cells and cell products, which scientists generally categorize as
biotechnology processes. That is, part (A) of the statutory definition applies only
to "single and multi-celled organisms" while part (B), which applies to isolated
cells, is limited to the production of cell lines through cell fusion procedures. 2
This indicates that all other processes involving isolated cells or cell products are
excluded under the statute (with the exception of those defined by part (C),
described below). In other words, the statutory definition leaves out various
biotechnological procedures, such as isolation of enzymes from animal and plant
22
sources, 2' incorporation of amino acids in food products and pharmaceuticals,
and even certain developments in stem cell research. 23

113 OXFORi)

It4

DI(71IONARY OFBIOCHEMISTRYANI)MOL.CUIAR BIOI)OGY, smpranote91, at 101.

Id.L

t N. Vriezen et al.,Mamma'an Ce//Culture,in BASIC BIOTEI:HNOI,O(;Y 449,450 (Colin Ratledge
& Bjorn Kristiansen eds., 2d ed. 2001).
' CAMPBEILL. F. AL., supra note 90, at G- 15.
...Id at 844.
...Id at 853.
"' See Vriezen et al., spranote 115, at 450 (noting infection with a virus and transfection with
an oncogene or mutagenesis as alternative methods for producing a continuous cell line for purposes
of protein production).
11, 35 U.S.C. § 103(b).
121 See David A. Lowe, Productionof Enymes, in BASIt; B1o"I[tCHNOJ X(;Y 393-95 (Colin Ratledge
& Bjorn Kristiansen eds., 2d ed. 2001) (noting isolation of enzymes from animal and plant products
as a good source of some enzymes).
"= See L. Eggeling et al., Amino Acds, in BAsi BiOT,(CHNOI .OGY 282 (Colin Ratledge & Blom
Kristiansen eds., 2d ed. 2001) (describing commercial uses of amino acids).
123 See, e.g., Antonio Regalado, Stem Cells Without Clonin, WAiL S.J., Feb. 1, 2002, at B1 (noting
fertilization and parthenogenesis (i.e., electrical or chemical stimulation) as alternative procedures to
cloning in stem cell production).
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The statutory definition includes one further category of "biotechnology
process" in part (C), providing that a method of using a product created by a
process in part (A) or (B) is also a "biotechnology process.' 24 This provision
expands "biotechnology processes" to include all uses of products from any of
the above-mentioned procedures, encompassing even some processes which
scientists typically would not consider biotechnology. For example, a simple
combination of two drugs 121 could constitute a biotechnology process under this
definition. Furthermore, part (C) creates an artificial distinction between methods
of using a biological material produced by a part (A) or (B) procedure and those
which are not. For example, any use of a hormone produced through a
recombinant DNA technique within part (A) is a "biotechnology process" under
part (C), while the use of the same hormone produced through chemical
synthesis 126 only qualifies as a biotechnology process if it meets the requirements
of part (A) or (B).
III. ANALYSIS
Despite Congress's intent in passing the Biotechnology Process Patent Act of
1995 to relieve inconsistent determinations within the Patent Office,' 2' the Act
actually creates even greater inconsistencies in our nation's patent law than
previously existed. First, the Act unjustifiably singles out biotechnology processes
as exempt from the standard nonobviousness requirement in certain situations.
Second, the Act extends this exemption beyond process claims utilizing novel and
nonobvious starting materials to those merely producing novel and nonobvious
resultant products. The Biotechnology Process Patent Act of 1995 is therefore
simultaneously too restrictive in the scope of subject matter covered and too
broad in the application of its exemption from the nonobviousness requirement.

12435 U.S.C.

§ 103(b).

' See Amy Tsao, Superpills with a One-Two Punch, Businessweek Online, Oct. 9, 2003, at http://

www. businessweek.com/technology/content/oct2003/tc2003109_337.htm (commenting on the
new trend of pharmaceutical companies to produce combination pills composed of two or more
commonly-used component drugs).
121 SeeGeorgeB. Kresse, RecombinantProteinsofHighValue, inBASICB1OTECHNOI.OGY 436 (Colin
Ratledge & Bjom Kristiansen eds., 2d ed. 2001) (noting chemical synthesis of proteins as a feasible
alternative to gene technology).
127 H.R. RrP. No. 104-178, at 1-2 (2000), reprintedin1995 U.S.C.C.A.N. 395,395-396; 141 CONG.
RrC. 28072 (1995) (statement of Sen. Hatch) (noting that the purpose of the legislation is to "resolve
delays and inconsistent determinations faced by biotechnology patentees under present PTO
practices").
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A. THE SCOPE OF SUBJECT MATTER

The Biotechnology Process Patent Act of 1995 is too restrictive in the scope
of subject matter covered and should at least apply to chemical process claims as
well as biotechnology process claims, if not to process claims generally. While the
statutorily-provided exemption from the nonobviousness requirement for certain
biotechnology processes is most likely constitutional,' 2 the exemption is a poor
policy which creates inconsistency and inequality in our patent system. By
providing this exception for biotechnology processes, Congress implies that this
rule is not available for other types of process claims, 29 perhaps foreclosing an
otherwise reasonable judicial interpretation to the contrary. This is especially
problematic for chemical process claims, which are similar and even overlap with
biotechnology process claims,' 3 yet are subjected to a different nonobviousness
analysis under the statute. 3 1
Because of the significance courts have attached to the nonobviousness
requirement for over a century,13 2 a statutory exemption from this key
requirement raises a question of constitutionality. The Biotechnology Process
Patent Act of 1995 is probably authorized, however, under the United States
Constitution.'33 That is, while the nonobviousness requirement plays an
important role in determining the patentability of inventions," nonobviousness
does not seem to be constitutionally mandated.' It is therefore within the power

Paul J. Heald & Suzanna Sherry, Impbed Limits on the Legislative Power The IntellectualProperty
Clause as an Absolute Constrainton Congress, 2000 U. Iii,,. L. RWV. 1119, 1185.
' See H.R. R.I,. No. 104-178, at 4-5 (2000) (noting the Act's application to biotechnology
processes only); 141 CON(;.RiEC:. 28074 (1995) (statement of Sen. Hatch) (commentingon the failure
of previous legislation which applied to processes generally).
I' See 7 PHYSICS AND CHIFEMISIRY BASIS op BIo)ICHNOi)O(;Y 4 (Marcel de Cuyper & JeffW.
M. Bulte eds., 2001) (identifying the importance of applying physical and chemical principles to
biotechnology); FRANCIS FUKUYAMA, OUR POSTHUMAN FuTtFu,: C()NSIQ.UF.NCICS OF THI;
Bi YrECHNOI x.;Y RIv iUT] ON 19 (2002) (pointing out that biotechnology draws from many areas
of science).
"3'See 2 JOHN GI.ADISTONI MIS III j-.' \.., PATE.NT LAW FUNDAM.N'AI. § 10.36 (2d ed.
2003) (declaring that as a result of the Biotechnology Process Patent Act of 1995 "a legal (as opposed
to a factua) distinction now exists between the patentability of biotechnological and nonbiotechnological processes") (emphasis in original).
312See Hotchkiss v. Greenwood, 52 U.S. (11 How.) 248 (1851) (requiring nonobviousness for
patentability); Graham v. John Deere Co., 383 U.S. 1 (1966) (noting the codification of the
nonobviousness requirement in the Patent Act of 1952).
"' Heald & Sherry, supra note 128, at 1185.
131See M.RGF,S r A.., supra note 12, at 112 (identifying nonobviousness as the ultimate
requirement for patentability).
'3 See Heald & Sherry, supra note 128, at 1184 (reasoning that, while the Constitution requires
more than novelty, Congress has "substantial discretion in determining how high a degree of
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of Congress to provide an 36exemption from the nonobviousness requirement for
biotechnology processes.
Although providing an exemption from the nonobviousness requirement for
certain biotechnology processes may be constitutional, it is an imprudent policy
which creates inconsistency in our patent system. The United States Supreme
Court has repeatedly emphasized the importance of the nonobviousness
requirement as a limit on patent monopolies. 3 ' Congress should not permit an
exemption to this fundamental requirement without a solid justification for doing
so. In regard to the Biotechnology Process Patent Act of 1995, there is no good
reason, in law or in science, to provide an exemption from the nonobviousness
requirement for certain, statutorily defined biotechnology processes.
/. Lack of a Scienific Justification. Though the current law provides a special
exemption from the nonobviousness requirement for biotechnology processes,
there is no scientific basis for Congress to distinguish between biotechnology and
other types of process claims. The disparity is particularly blatant in the context
of chemical processes, which are similar to, and often overlap with, biotechnology
processes3 5 yet are not entitled to the same nonobviousness analysis under the
statute. Additionally, through its statutory definition of "biotechnology
processes," the Act creates an unfounded division within the field of
biotechnology itself by including certain types of biotechnology processes while
excluding others.
A significant problem with the Biotechnology Process Patent Act of 1995 is
that it creates an artificial distinction between biotechnology and chemical

processes. While scientists and laypersons alike often refer to biotechnology as
one field of science among many others, no field of science is truly
independent.'39 Neurologists study biological systems, biologists utilize chemistry

techniques, and chemists draw on the principles of physics." 4 Similarly, scientists
working in the field of biotechnology constantly rely on the principles and
methodology of other scientific disciplines, including chemistry.' 4' At a very basic

level, every living being is made up of cells, which in turn are made up of

innovation it will require").
116 Id at 1185.
2 DONALD CHISUM, CHISUM ON PAEN'S § 5.01 (2002).
See 7 PHYSICS AND CHEMISTRY BASIS OF BIOTECHNOLOGY, supranote 130, at 4 (highlighting
the importance of applying physical and chemical principles to biotechnology); see also FUKUYAMA,
supranote 130, at 19 (noting that biotechnology incorporates techniques from many other areas of
science).
139 CAMPBE.L, FI' AL.., supra note 90, at 22.
148 Id at 22; MARIE T. BANICH, COGN1TIVE NEUROSCIENCE ANDNEUROPSYCHOLOGY 4-5 (2d
18

ed. 2004).
at 14; CAMPBElJ. ET AL., supra note 90, at 364.
141 Manning, supra note 1,
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molecules, which are the base units of all chemical compounds." In a way, then,
all biotechnology processes are actually chemical processes; they are just limited
to those chemical processes that involve the manipulation of biochemical
products (such as proteins and nucleic acid base pairs) or chemical processes
within biological systems. Furthermore, chemical and biotechnology products
and processes often serve similar functions; for example, pharmaceutical
companies use both chemical and biotechnology processes in the production of
new drugs." 3 Accordingly, distinguishing between such closely related subject
matter by applying a different nonobviousness analysis to biotechnology and
chemical process patents makes little sense from a scientific standpoint.
The Act is even more illogical in its definition of "biotechnology processes"
in that the statutory definition creates an artificial distinction within the field of
biotechnology itself. Specifically, the statute excludes some processes generally
considered biotechnology, including methods for producing a cell line other than
cell fusion (part (B))"' and various methods involving isolated cells or cell
products." 5 At the same time, the inclusion of any process inducing an organism
to exhibit an unnatural physiological characteristic" 6 (part (A), clause (iii)) and any
method of using a biotechnologically-produced product"' (part (C)) brings in
processes from outside the realm of biotechnology.
The Act may further create an unreasonable distinction between
biotechnology and other processes generally. The nonobviousness requirement
serves the general purpose of preventing patent monopolies on inventions which
fail to advance the state of the useful arts."' Therefore, in passing industryspecific legislation which provides a different nonobviousness analysis for certain
types of process claims, Congress should have a reasonable justification for
circumventing the traditional nonobviousness requirement. Congress, in passing

iA,., supra note 90, at 22.

"2

C

1.

LEEr., supra note 8, at 79.

.

. See Vriezen et al., supra note 115, at 450 (identifying infection with a virus and transfecion
with an oncogene or mutagenesis as two alternative methods to cell fusion for producing a
continuous cell line).
"4 See, e.g., Eggeling et al., supra note 122, at 282 (discussing the incorporation of amino acids
in
some food products and pharmaceuticals); Lowe, supranote 121, at 393-95 (describing isolation of
enzymes from animal and plant products); Regalado, supra note 123, at BI (noting fertilization and
parthenogenesis (i.e., electrical or chemical stimulation) as alternative procedures to cloning in stem
cell production).
141 See WIBsiBSTI.R's II:

NiEW RIvI,-ISII)ni- UNIVIFSHY DIciIONARY, supra note 108, at 887
(suggesting that a new physiological characteristic broadly refers to any change in the normal
functioning of a living organism).
147 See, e.g., Tsao, supra note 125 (commenting on the new trend of pharmaceutical companies to
produce combination pills composed of two or more commonly used component drugs).
141 CHISUM, supra note 137, § 5.01.
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the Biotechnology Process Patent Act of 1995, has provided no such justification.
The legislative history does reveal objections to extending the nonobviousness
exemption to software, electronic, and machinery claims. 9 Even if the unique
nature of software claims' might entitle them to a separate nonobviousness
analysis, however, such an argument would support special treatment for software
patents rather than for biotechnology patents.' 5 1 Generally, in the absence of any
compelling justification, Congress should not supply special exceptions, such as
the 1995 Act's exemption from the nonobviousness requirement for
biotechnology processes, in patent law.
2. Lack of a Legal Justification. Though Congress addresses its reasons for
passing the Act,' 2 these stated reasons fall short of providing a sound justification
for the creation of a nonobviousness exemption specifically limited to
biotechnology processes. In particular, in discussing the legislation, no member
of Congress offered a single policy reason for singling out biotechnology process
claims from other types of process claims. In fact, earlier versions of the bill,
including the original 1990 Act, would have established a broad nonobviousness
exemption for process patents,' 53 suggesting that the bill drafters recognized this
as a more favorable approach. Later, in considering the 1995 Act, members of
both Houses pointed to the failure of this previous broad legislation as a reason
for limiting the scope of the 1995 Act to biotechnology processes.' 54 This,
coupled with an indication of strong pressure from pharmaceutical and
biotechnology companies, 55 suggests that Congress limited the scope of the 1995
Act to biotechnology processes simply to satisfy the demands of special interest
groups rather than to achieve any beneficial patent policy.
In passing the Biotechnology Process Patent Act of 1995, Congress not only
failed to provide a policy basis for singling out biotechnology process claims but

" H.R. Rip. No. 102-1085, at 109 (1992).
1', See, e.g., State St. Bank & Trust v. Signature Fin. Servs., 149 F.3d 1368, 47 U.S.P.Q.2d (BNA)
1596 (Fed. Cir. 1998) (suggesting that a software system might be patentable as a machine rather
than a process).
'5' But see Lorance L. Greenlee, Biotechnology Patent Law: Perspective of the FirstSeventeen Years,
Propective on the Next Seventeen Years, 68 DFENV.U. L. Riv. 127, 129 (1991) (suggesting an analogy
between biotechnology and software processes by characterizing DNA as "a read-only memory for
programming biological systems").
132 H.R. RF".'. N). 104-178, at 1-2 (1995), reprintedin1995 U.S.C.C.A.N. 395,395-396; 141 CONG.
RE,
. 28072 (1995) (statement of Sen. Hatch).
15. H.R.1417, 102d Cong. (1991); S.654, 102d Cong. (1991); 74 H.R. 3957, 101st Cong. (1990);
S.2326, 101st Cong. (1990).
'5' See supra notes 72-73 and accompanying text.
1.55
See Burk, supra note 43, at 71 (noting extensive lobbying efforts by Genentech, Amgen, and
other biotechnology companies which "spawned successive drafts of the proposed legislation, each
of which did new violence to the current state of the patent law").
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also actually undermined one of the purposes it set out to achieve. Specifically,
the legislative history indicates that one of Congress's main purposes in enacting
this legislation was to resolve inconsistencies in the patent law created by "two
conflicting and irreconcilable decisions" in the Federal Circuit: In re Durden and
In re Pleuddemann. s6 The Biotechnology Process Patent Act of 1995, however,
applies only to biotechnology processes and would therefore have no effect on
chemical process cases like Durdenand Pkuddemann. In fact, the Act actually seems
to create a new inconsistency by drawing a distinction between the law on
chemical process patents and the law on biotechnology process patents.
The new section 103(b) of the Patent Code singles out biotechnology process
claims-as defined in the statute-and provides an exemption from the
nonobviousness requirement for claims which use or result in novel and
nonobvious compositions of matter. 7 In specifically naming and defining
"biotechnology processes," the Act clearly indicates that other types of process
claims, such as those for chemical processes, are not covered under the Act.
Additionally, the legislature's strict focus on biotechnology processes and
objections to legislation that was broader in scope"' suggests that the 1995 Act
may actually foreclose the Federal Circuit's subsequent attempts, starting with In
re Ochiai,' 9 to establish a similar rule for chemical process claims.
Just one month after Congress passed the Biotechnology Process Patent Act
of 1995, the Federal Circuit itself attempted to alleviate the confusion following
6
The Ochiai court effectively
its Durden decision in the case of In re Ochiai.""
6
overruled Durden," ' holding that a chemical process is not obvious where the
process utilizes a novel and nonobvious starting material to create a novel and
nonobvious product.'62 The Federal Circuit then expanded its ruling just three
months later in the case of In re Brouwer, this time holding that a chemical process
is not obvious where the resultant product-rather than the starting material-is
new and nonobvious' 63 The combined result of Ocbiai and Brouweris to provide
a rule for chemical processes similar to the rule that the Biotechnology Process
Patent Act of 1995 provides for biotechnology processes.

H.R. REP. No. 104-178, at 3.
35 U.S.C. § 103 (2003).
158See H.R. REP. No. 102-1085, at 109 (1992) (recognizing concerns that House Bill 1417 would
16

157

apply to inventions outside the field of biotechnology, including inventions "in the areas of
electronics, computer technology, chemicals, mechanical engineering and machinery").
"' In re Ochiai, 71 F.3d 1565, 37 U.S.P.Q.2d (BNA) 1127 (Fed. Cir. 1995).
160 Id
161 But see id at 1570 (avoiding outright rejection of Durden as a case "turning on specific facts").
162 Id at 1565.
161 In re Brouwer, 77 F.3d 422 (Fed. Cir. 1996).
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Although the rules are similar in effect, there are two noteworthy differences
between the statutory law of the Biotechnology Process Patent Act of 1995 and
the judicial rule of the two Federal Circuit decisions. First, while the statute is
expressly limited to biotechnology processes, 164 the rule established in the two
6
Federal Circuit decisions is not expressly limited to chemical processes. 1
Second, while the statute presents an exemption not otherwise provided, 66 the
court is simply interpreting the process invention "as a whole"' 167 to include the
starting material 68 and resulting product.'69 Because the court has not expressly
limited its rulings to chemical processes and because the rule is based on a
straightforward interpretation of the Patent Code (which applies to patents
generally), the judicial rule may reasonably apply to other types of process claims.
Though the Ochiaicourtintended to finally resolve the confusion following the
Durden decision, and provided what otherwise may have been the clearest and
most accurate interpretation of the statutory law on process patents to date, the
court's holding may actually violate the Biotechnology Process Patent Act of
1995. That is, persuasive evidence demonstrates that the Federal Circuit's
holdings in Ochiai and Brouwer contradict both the language and history of the
1995 Act. First, the Act itself provides a nonobviousness exemption not
otherwise provided, which it explicitly limits to biotechnology processes.' 7' The
fact that Congress believed an exemption was needed at all suggests that the
starting material and resulting product are not naturally part of the invention "as
a whole."' 7 ' If they were, a novel and nonobvious starting material or resulting
product would already be adequate to establish the nonobviousness of any
process. A broader statute applying to all process claims could be viewed as a
simple codification of this interpretation; however, by limiting the statute to
biotechnology processes, Congress has provided a special exemption for
biotechnology process claims that is distinguishable from the law governing other
types of process claims.
Second, the legislative history of the Biotechnology Process Patent Act of
1995 reveals (1) the failure of several previous bills applying to process claims
generally and (2) Congress's awareness of these failures and objections to a

" 35 U.S.C. § 103(b) (2003).
In r Ochiai, 71 F.3d 1565; In re Brouwer,77 F.3d 422.
See 35 U.S.C. § 103(b) ("Notwithstanding [the nonobviousness requirement of] subsection
(a) ... a biotechnological process using or resulting in a composition of matter that is novel... and
nonobvious... shall be considered nonobvious . ..
167 35 U.S.C. § 103(a).
11 In ra Ocbiai, 71 F.3d 1565.
269 In re Brouwer, 77 F.3d 422.
"i,

35 U.S.C. § 103.
171

Id.
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broader bill.'72 In other words, not only does the Act explicitly apply only to
biotechnology processes, but also the legislative history indicates that Congress
purposely drafted this limitation in order to exclude other types of process claims,
including those for chemical and software patents. While there is no policy basis
for drawing such a distinction between biotechnology and other types of process
claims, the legislative intent is clear. Congress did not want the rule that novel
and nonobvious starting materials or resulting products establish the
nonobviousness of a process to apply to chemical, software, or other nonbiotechnology process claims.
Ironically then, the 1995 Act, while purporting to alleviate inconsistencies in
the patent system, 73 not only creates a new inconsistency (in distinguishing
between biotechnology and other types of process claims) but also may preclude
the court from alleviating the inconsistency judicially. Thus, the Federal Circuit's
decisions in Ochiai and Brouwer, holding that chemical processes are nonobvious
where the starting material or resulting product is novel and nonobvious, may in
fact violate the Biotechnology Process Patent Act of 1995.174 Until the courts or
Patent Office recognize this contradiction, however, patent applicants will retain
the benefit of these judicial decisions. As it stands now, the Federal Circuit clearly
has not noticed this possible dilemma,"5 and the Patent and Trademark Office
seems ignorant of it as well, applying both the statutory and judicial rules to patent
applications." 6
B. APPLICATION OF THE EXEMPTION

Even as the Act is too narrow in the scope of subject matter covered, the
Biotechnology Process Patent Act of 1995 is concurrently too broad in the
application of its exemption. Specifically, the statute should provide that processes
with novel and nonobvious starting materials, but not those with merely novel and
nonobvious resulting products, are nonobvious themselves. In this sense, the 1995
Act went too far in its attempt to overrule Durden, a case involving both novel and

172 See supra note 72 and accompanying text.

173H.R. REP. No. 104-178, at 1-2(1995), reprintedin1995 U.S.C.C.A.N. 395,395-396; 141 CONG.
REC. 28072 (1995) (statement of Sen. Hatch).
' See In re Broumwr, 77 F.3d 422; In re Ochiai, 71 F.3d 1565.
175 See In re Brouwer, 77 F.3d 422 (finding a chemical process nonobvious where a resultant
product is novel and nonobvious); In r Ochiai,71 F.3d 1565 (finding a chemical process nonobvious
where a starting material is novel and nonobvious).
176See PTO Notice, Guidance on Treatment of Productand Process Claims in Light oflin re Ochiai, In
re Brouwer, and35 U.S.C if 103(h), 1184 OFF. GAZ. PA'r. O1.. 86 (Mar. 26, 1996) [hereinafter PTO
Notice] (directing patent examiners to apply the Ochiai and Brouwerdecisions to process claims).
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nonobvious starting materials as well as novel and nonobvious resulting products.'7 7
In order to overrule Durden, Congress could simply have articulated a rule that
proper analysis of process inventions "as a whole"'78 includes a consideration of the
starting materials but not the resulting products.'79
Congress may have avoided establishing that rule because of the confusion

resulting from the using-making distinction of Pleuddemann.'" The Pleuddemann
decision likely caused this confusion, however, because the court failed to articulate
the rule clearly' and because the court used Durden,a case involving both a method
of using a novel material and a method of making a novel product, as its primary
example of a "method-of-making" case. 182 While critics of the using-making
distinction correctly point out that all processes are, at some level, processes of
using some materials to make other materials, 83 the distinction becomes rational
when the focus is on the starting materials versus the resultant products. Thus, in
assessing process claims, patent examiners-and judges-should consider the
starting materials used in the process but not the resultant products made by the

process as part of the process invention "as a whole."' ' That analysis finds support
in both previous and subsequent case law' 85 as well as in plain logic.
Though the Pkuddemann decision may be too convoluted to provide a useful
analysis,S'Judge Rich (the author of both the Durden and Pkuddemann opinions) set
forth a clear distinction between novel, nonobvious starting materials and novel,
nonobvious resulting products in the earlier case of In re Manfg. 8 7 The Mang court
emphasized that the statutory standard for nonobviousness demands a
consideration of the process "invention as a whole."'" The court then suggested

'" See In reDurden, 763 F.2d 1406, 226 U.S.P.Q. (BNA) 359 (Fed. Cir. 1985) (affurming the
rejection of a patent application on nonobviousness grounds).
178 35 U.S.C. § 103(a).
171See In reMancy, 499 F.2d 1289, 182 U.S.P.Q. (BNA) 303 (C.C.P.A. 1974) (adopting such an
interpretation).
" See In rePleuddemann, 910 F.2d 823,15 U.S.P.Q.2d (BNA) 1738 (Fed. Cir. 1990) (attempting
to distinguish between methods of making novel products, which may be obvious, and methods of
using such products, which are nonobvious).
at 827 ("[T]he compounds and their use are but different aspects of, or ways of looking
181 See id.
at, the same invention and consequently that invention is capable of being claimed both as new
compounds or as a new method or process. ..
182 Id.
183 E.g., Leon Radomsky, CanProcess C/aims that Include New and UnobtiousProductLimitationsStill

Be Obvious After In re Ochiai?, 79 J. PAT. & TRADEMARK OFF. SoC'Y 567, 588-89 (1997).
184 35 U.S.C. § 103(a).
185 E.g., In reMany, 499 F.2d 1289; In reOchiai, 71 F.3d 1565.
188 Burk, supra note 43, at 56-57.
187 In re
Mangy, 499 F.2d 1289.
8 Id.at 1292.
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that a starting material is part of the invention as whole." 9 In particular, the court
reasoned that one skilled in the art would not find it obvious to utilize a novel
starting material because, as the court succinctly notes, "one cannot choose from
the unknown."' 90 In contrast, the court implied that a novel resulting product does
not speak to the obviousness or nonobviousness of the process. 9' In other words,
the resulting product, unlike the starting material, is not logically part of the process
invention as a whole.
Despite the fact that the Many decision was issued almost thirty years ago,
courts continue to approve of its holding and its distinction between novel starting
materials and novel resulting products. As recently as December 1995, the Federal
Circuit cited Mang with approval' 92 Specifically, the Ocbiai court concurred with
the Mangy court's reasoning that "one cannot choose from the unknown" and
similarly concluded that a novel, nonobvious starting material establishes the
nonobviousness of the process. 93 Though shortly thereafter the Federal Circuit
held that a novel, nonobvious resultant product is also adequate to establish the
nonobviousness of a process, 94 the court has since backed away from this rule.'
In July 2003, the Federal Circuit suggested in dicta that a new and nonobvious
resultant product may not be relevant to an assessment of the obviousness of a
process claim.' 96 This supports the view that the starting materials, but not the
resulting products, are part of the process invention as a whole and are thus relevant
to a determination of the nonobviousness of a process claim.
IV.

CONCLUSION

Despite these problems with the Biotechnology Process Patent Act of 1995, the
revised statute has had surprisingly little practical effect. This may be due in part to
one peculiar feature of the nonobviousness exemption: in order for the Patent
Office to apply the exemption, a patent applicant must expressly claim it.' 97 Patent

19

Id. at 1293.

'90 Id. at

1293.
"'1See id. at 1293 (noting that the novelty of the starting material may lend nonobviousness to
a method-of-use while the novelty of the product may not lend such nonobviousness to a process
of making).
192In reOchiai,71 F.3d at 1570.
193 Id. at 1570.
194 In reBrouwer, 77 F.3d 422 (Fed. Cir. 1996).
195See Torpharm,Inc., 336 F.3d at 1327 (suggesting that novelty of a resulting product may not be
adequate to support a finding of nonobviousness of a process).
196 Id.at 1327 ("A process yielding a novel and nonobvious product may nonetheless be obvious;
conversely, a process yielding a well-known product may yet be nonobvious.").
197 35 U.S.C. 5 103 (2003); see also PTO Notice, supra note 176 (emphasizing that 5 103(b) applies
only where the patent applicant makes a "timely election" (by petition under 37 CFR § 1.182) to

https://digitalcommons.law.uga.edu/jipl/vol12/iss1/8

24

Alley: The Biotechnology Process Patent Act of 1995: Providing Unresolve

2004]

BIOTECHNOLOGY PROCESS PATENTACT

applicants may be reluctant to assert the exemption because the presumption of
validity of a claim obtained pursuant to section 103(b) rests on the novelty and
nonobviousness of the underlying composition of matter. 9 ' Applicants may be
unwilling to risk losing the benefits of the presumption of validity, particularly
where there are alternative arguments for nonobviousness.
A second, and perhaps more fundamental, reason for the Act's lack of influence
may stem from the fact that the courts and the Patent Office consider the Federal
Circuit's decisions in Ocbiai and Brouwer applicable to biotechnology process
claims.1 That is, applying these two cases may achieve a similar result for process
claims generally as applying the statute would achieve for biotechnology process
claims. Thus, patent applicants and examiners may simply be relying on this judicial
rule rather than on the more complex, limited statutory rule.2' This is problematic
because statutory law trumps case law and the Act seems to foreclose the Ochiai
court's rulings in regards to chemical processes. Thus, while the Patent Office may
be applying the law as it should be by relying on the Ocbiairule for chemical process
claims,2' that application does not accurately reflect the law as it truly stands.
Before Congress passed the Biotechnology Process Patent Act of 1995, the
Federal Circuit or Supreme Court could have resolved the inconsistencies resulting
from the Durden and Pkuddemann decisions by holding that the use of a novel and
nonobvious starting material establishes the nonobviousness of a process. In fact,
the Federal Circuit held exactly that in Ochiai.2' Because the limited scope of the
1995 Act suggests that such a judicial interpretation is not available, however, the
Federal Circuit's decision (or any court decision for that matter) is not adequate to
resolve this new discrepancy between the law for biotechnology process patents and
the law for all other types of process patents. Additionally, since the revised statute
is most likely constitutional," 3 the Supreme Court is unlikely to step in and

proceed under this section).
'9' See STEPHEN A. BECKER, 1 PATENT APPLICATIONS HANDBOOK § 2:25 (2003) (noting the
amendment to 35 U.S.C. S 282 as a major caveat to the Biotechnology Process Patent Act of 1995).
9 See, e.g., ExparteLee, 1995 WL 1696759 (Bd. Pat. App. & Interf.) (remanding a Durden-type
rejection of a biotechnology process claim for further consideration in light of In re Ochieu); Exparte
Reider, 1995 WL 1692980 (Bd. Pat. App. & Interf.) (reversing a patent examiner's rejection of a
biotechnology process claim based on the Ochiaiand Bruewer decisions).
2 See BECKER, supra note 198, § 2:25 ("As a result of the Federal Circuit decisions, it is unclear
whether [the Act] will provide applicants with any benefit... .
20' See PTO Notice, supranote 176 (proclaiming that, in light of Ocbiaiand Brouwer,Patent Office
personnel must consider all claim limitations, including "language in a process claim which recites
making or using a nonobvious product," to analyze process claims); UNITED STATES PATENT &
TRADEMARK OFFICE, MANUAL OF PATENT ExAMflNING PROCEDURe

§

2116.01 (8th ed. 2003)

(suggesting that the Ochiai and Brouwer decisions apply to process claims generally).
202 In re Ochiai, 71 F.3d 1565, 37 U.S.P.Q.2d (BNA) 1127 (Fed. Cir. 1995).
203 Heald & Sherry, supra note 128, at 1185.
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invalidate the Act. This leaves Congress to remedy the predicament it has created.
Considering that the legislature previously rejected bills which were broader in
scope' and that even the courts and the Patent Office appear oblivious to the
dilemma," 5 Congress seems unlikely that will choose to pass corrective legislation
any time soon.
Nonetheless, if Congress considers remedial legislation, that legislation should
address several issues. First, the legislation should apply to all types of process
claims, not just to those that meet a statutory definition of "biotechnology."
Though this kind of broad legislation failed to pass earlier sessions of Congress, it
is necessary to correct the current discrepancy in the law for biotechnology
processes (as defined by statute) as compared to all other types of process claims.
Second, the legislation should provide interpretative guidance rather than an
exemption not otherwise provided. In other words, a corrective bill should include
language indicating that consideration of the process invention "as a whole"
includes the starting material and, for this reason, a novel and nonobvious starting
material establishes the nonobviousness of a process. Finally, new legislation should
indicate that resultant products, in contrast to starting materials, are not part of the
process invention as a whole and thus their novelty and nonobviousness are
irrelevant to the nonobviousness of a process. Though Congress failed to make this
distinction in the Biotechnology Process Patent Act of 1995, the courts have
suggested such a distinction is appropriate.206 Oddly, a bill similar to the 1990
Act,'07 the first predecessor to the 1995 Act, would satisfy all of these conditions.
BECCA ALLEY

204 See H.R. REP. NO. 102-1085, at 109 (1992) (noting the failure of House Bill 1417); 141 CONG.

REC. 21543 (statement of Sen. Hatch) (1995) (noting the failure of House Bill 4307).
20 The Federal Circuit's decisions in In re Ochiai and In re Brouwer jointly establish a rule for
chemical process claims which may be foreclosed by the Biotechnology Process Patent Act of 1995.
See In re Brouwer, 77 F.3d 422 (Fed. Cir. 1996) (holding that a novel and nonobvious resulting
product establishes the nonobviousness of a chemical process); In re Ocbiai, 71 F.3d 1565 (holding
that a novel and nonobvious starting material establishes the nonobviousness of a chemical process).
See also PTO Notice, supra note 176 ("In view of the Federal Circuit's decisions in Ochiaiand Brouwer,
an applicant's need to rely upon § 103(h) should be rare.").
206 In re Mancy, 499 F.2d 1289, 182 U.S.P.Q. (BNA) 303 (C.C.P.A. 1974); In re Ochiai, 71 F.3d
1565; Torpharm, Inc. v. Ranbaxy Pharmaceuticals, Inc., 336 F.3d 1322 (Fed. Cir. 2003). But see In
re Brouwer, 77 F.3d 422 (holding that a novel and nonobvious resultant product establishes the
nonobviousness of a process).
207 See 136 CONG. REG. 5182 (1990) (statement of Sen. DeConcini) (noting that the 1990 Act
would have stating that a process of making a product shall not be considered obvious under this
section if an essential material used in the process is novel under section 102 and otherwise
nonobvious under section 103).
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